POSTERIOR SUB-TENON'S Avastin

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00567372
First received: November 30, 2007
Last updated: December 5, 2008
Last verified: December 2008

November 30, 2007
December 5, 2008
June 2008
November 2008   (final data collection date for primary outcome measure)
macular volume [ Time Frame: baseline, 3,6 and 12 weeks ] [ Designated as safety issue: No ]
Best corrected visual acuity [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00567372 on ClinicalTrials.gov Archive Site
  • macular thickness [ Time Frame: baseline,3,6 and 12 weeks ] [ Designated as safety issue: No ]
  • best corrected visual acuity [ Time Frame: baseline, 3,6 and 12 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
POSTERIOR SUB-TENON'S Avastin
POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA

Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema

Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diffuse Diabetic Macular Edema
Drug: bevacizumab (Sub-tenon´s injection)
a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
7
June 2009
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat thickness ≥250 μ BCVA ≥ 20/400 Without any treatment

Both
25 Years to 90 Years
No
Contact: Sandra Vera-Rodriguez, MD 525510841400 ext 1171 retinamex@yahoo.com
Mexico
 
NCT00567372
00922
No
Sandra Vera-Rodriguez, Asociación para Evitar la Ceguera en Mexico IAP
Asociación para Evitar la Ceguera en México
Not Provided
Principal Investigator: Sandra Vera, MD Asociación para Evitar la Ceguera en Mexico
Principal Investigator: Hugo Quiroz-Mercado, MD Denver Health Medical Center
Principal Investigator: Adai Pérez-Montesinos, MD Asociación para Evitar la Ceguera en Mexico
Asociación para Evitar la Ceguera en México
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP